Trend
DailyDowntrend (confirmed)
4 hourLeaning Bullish
1 hourBullish
15 minBearish
5 minNo data
Daily trend turns up above $112.09
Key levels
Support$112.09
Support$109.11
Latest news & SEC filings
No headlines in the last 90 days.
· Healthcare
SEPT Low Target
$116.00
SEPT Mid Target
$124.00
SEPT High Target
$125.00
Analyst Consensus
$124.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for NUVL.
Start Free Trial →Valuation Verdict
OVERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$102.44
12
Moat Score
NONE
1/9
Piotroski Score
32.1
Altman Z-Score
Insider Signal
SELLING
0 buys / 8 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Wheeler Cameron | director | Buy | 3,444 | - | Jun 16, 2026 |
| Srivastava Sapna | director | Buy | 3,444 | - | Jun 16, 2026 |
| Squarer Ron | director | Buy | 3,444 | - | Jun 16, 2026 |
| Protopapas Anna | director | Buy | 3,444 | - | Jun 16, 2026 |
| Oliger Christy J. | director | Buy | 3,444 | - | Jun 16, 2026 |
| Meyers Michael L. | director | Buy | 3,444 | - | Jun 16, 2026 |
| Bogle Grant C. | director | Buy | 3,444 | - | Jun 16, 2026 |
| Flynn James E | director 10% owner | Buy | 3,444 | - | Jun 16, 2026 |
| Noci Darlene | officer | Buy | 10,000 | $11K | Jun 9, 2026 |
| Noci Darlene | officer | Buy | 685 | $5K | Jun 9, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-48.85%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
SEPT's Trading AI has generated a free, downloadable PDF research report for Nuvalent, Inc. (NUVL) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (0 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Nuvalent, Inc. (NUVL) is at $123.96, up 0.02% (+$0.02) at the Jul 14, 2026 close.
The average analyst price target for NUVL is $124.00, ranging from $116 to $125, based on 10 analysts. Latest: Bernstein downgrade on Jun 24, 2026.
Analyst ratings for NUVL: 2 Buy, 10 Hold, 3 Sell — consensus Hold.
NUVL last reported on May 7, 2026: EPS -$1.39 vs -$1.35 expected — a miss of 3.0%.
NUVL does not currently pay a dividend.
Support: $112.09, $109.11, $106.48.
Insider activity: SELLING, 0 buys and 8 sells in the last 90 days.